• 1. Design, synthesis and cytotoxic activity of water-soluble quinones with dibromo-p-benzoquinone cores and amino oligo(ethylene glycol) side chains against MCF-7 breast cancer cells
  Leon F. Scherz,Engy A. Abdel-Rahman,Sameh S. Ali,A. Dieter Schlüter,Mona A. Abdel-Rahman Med. Chem. Commun. 2017 8 662
• 2. Amphipathic metal-containing macromolecules with photothermal properties
  Xumin He,Xiehua He,Shenyan Li,Kaiyue Zhuo,Weixiang Qin,Shuyu Dong,Jiangxi Chen,Lei Ren,Gang Liu,Haiping Xia Polym. Chem. 2017 8 3674

• Solvents and Organic Chemicals Organic Compounds Organic 1,3-dipolar compounds Allyl-type 1,3-dipolar organic compounds Azo imides

Comprehensive Overview of m-PEG2-Azide (CAS No. 215181-61-6): Properties, Applications, and Innovations

m-PEG2-Azide (CAS No. 215181-61-6) is a versatile PEG-based linker widely utilized in bioconjugation, drug delivery, and materials science. Its unique structure, featuring a short polyethylene glycol (PEG) spacer and an azide functional group, enables efficient click chemistry reactions, particularly in Cu-free and strain-promoted applications. This compound has gained significant attention due to its role in advancing biocompatible nanomaterials and targeted therapeutics, aligning with current trends in precision medicine and sustainable biomaterials.

The growing demand for m-PEG2-Azide is driven by its compatibility with bioorthogonal chemistry, a hotspot in modern research. Scientists frequently search for "PEG-azide applications" or "non-toxic crosslinkers," reflecting the need for safer alternatives in biomedical engineering. With its low immunogenicity and high solubility, this compound addresses key challenges in drug formulation and diagnostic probe development. Recent studies highlight its use in antibody-drug conjugates (ADCs), a rapidly expanding field in oncology therapeutics.

From a technical perspective, m-PEG2-Azide (CAS No. 215181-61-6) exhibits excellent water solubility and stability under physiological conditions, making it ideal for in vivo applications. Its MW ~134.13 g/mol and short PEG chain minimize steric hindrance while maintaining efficient ligand-receptor binding. Researchers often inquire about "PEG spacer length optimization" or "azide-PEG storage conditions," underscoring the importance of proper handling to preserve its reactivity. Innovations like pH-responsive PEGylation further enhance its utility in smart drug delivery systems.

The compound's role in nanoparticle surface modification is another trending topic. As interest grows in "PEGylated gold nanoparticles" and "stealth liposomes," m-PEG2-Azide serves as a critical tool for improving circulation half-life and tumor targeting. Its azide group readily reacts with alkynes or DBCO moieties via Staudinger ligation, enabling modular design of theranostic platforms. This aligns with the industry's shift toward multifunctional nanocarriers for combined imaging and therapy.

Quality control of m-PEG2-Azide (CAS No. 215181-61-6) remains a key concern, with frequent searches for "HPLC purity standards" and "azide quantification methods." Advanced techniques like MALDI-TOF MS and NMR spectroscopy are employed to verify its structural integrity. The compound's lyophilization compatibility also makes it suitable for long-term storage, addressing logistical challenges in global research collaborations. Notably, its use in mRNA vaccine stabilization has emerged as a cutting-edge application during the pandemic era.

Environmental and regulatory aspects further highlight m-PEG2-Azide's advantages. Unlike traditional crosslinkers, it generates non-toxic byproducts and complies with ICH Q3C guidelines for residual solvents. This positions it favorably in green chemistry initiatives, a priority for pharmaceutical manufacturers. Searches for "biodegradable PEG alternatives" often lead to derivatives of this compound, demonstrating its adaptability to sustainability-driven R&D.

Future directions for m-PEG2-Azide research include enzyme-responsive conjugates and 3D bioprinting scaffolds, areas with exponential growth potential. Its integration with CRISPR delivery systems and organ-on-chip technologies exemplifies the intersection of chemistry and biology. As the scientific community seeks "next-generation bioconjugation tools," this compound continues to evolve through structure-activity relationship (SAR) studies and computational modeling.

• 516493-93-9(Azido-PEG5-amine)
• 356046-26-9(Azido-PEG5-azide)
• 182760-73-2(1,14-Diazido-3,6,9,12-tetraoxatetradecane)
• 166388-57-4(Azido-PEG2-C2-amine)
• 86770-67-4(Azido-PEG4-alcohol)
• 857891-82-8(Azido-PEG8-amine)
• 134179-38-7(Amino-PEG3-C2-Azido)
• 101187-39-7(Azido-PEG3-azide)
• 86520-52-7(Azido-PEG3-alcohol)
• 89485-61-0(m-PEG12-azide)